Search
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Categories: Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Cytochrome P-450 SubstratesPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalMyasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersAdinazolam
go.drugbank.com/drugs/DB00546ExperimentalAdinazolam (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was first developed to enhance the antidepressant effects of alprazolam. It has never been approved...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZafirlukast
go.drugbank.com/drugs/DB00549ApprovedAnother leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. … Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCinacalcet
go.drugbank.com/drugs/DB01012ApprovedInvestigationalCinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesMethoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTopotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsProbenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalThe prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...
Synonyms: p-(Dipropylsulfamoyl)benzoic acidCategories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP3A Inducers